Machine Learning &
Experimental Validation
Meet Elion: A New Target Discovery Platform
MACHINE LEARNING
PREDICTIONS
Human targets are identified
and prioritized using ML
Human genes, phenotypes and diseases are connected to model systems, starting with Zebrafish
IN VIVO
VALIDATION
Targets are validated
in 48 hours
From genetic modification to disease phenotype, with in vivo bioassays, and quantified by computer vision
HIGH-CONFIDENCE
TARGETS, FASTER
Targets have higher confidence
in clinical translation
backed by validated gene-disease association, druggable targets, and generation of in vivo bioassays
Machine
Learning
Our patented Contingent AI™ understands relationships within the data to provide sophisticated insights.
We address data bias by iterating on machine learning models based upon decisions made in the pre-processing and feature engineering stages.
Experimental
Validation
We leverage zebrafish, cellular and other phenotypic animal models to validate in silico predictions in vivo experiments and genetically modify them in vitro and in vivo, to improve translation.
Using active learning and computer vision on validated models for cardiac, central nervous system and rare disorders, we rapidly incorporate new data into our machine learning models.
Speed to Validation with Automation and Computer Vision
Due to their high genetic similarity to humans and ease of genetic manipulation, zebrafish are an optimal translation model. At 48 hours old, zebrafish have developed complex vertebrate biology including brains and hearts, allowing study of multiple organ systems simultaneously.
Computer Vision automates the data capture and analysis of multi-dimensional cardiac features (e.g., heart rate, ejection fraction), behavioral features (seizure-like movement, velocity, activity), and morphological features (vascular or edema changes)
Interested in Partnering?
We seek partners with both a desire to transform drug discovery and access to rich patient data, whether it’s EMR data, genomics data or clinical trial data. We are also seeking partners to help advance our drug discovery programs in cardiac, neurodegenerative and rare diseases.
We are highly collaborative experts in machine learning, data science and drug discovery. Let’s chat.